Regeneron Entered into Amended and Restated License Agreement with Sanofi for Libtayo (cemiplimab) to Treat Cancer
Shots:
- Sanofi to receive $900M up front, $100M in regulatory milestones, 11% royalty on net sales of Libtayo & $100M in sales-related milestones over the next 2yrs. The transaction is expected to close in Q3’22
- Regeneron to get exclusive license rights for the development, commercialization & manufacturing of Libtayo. Regeneron will increase the share of its profits from 10% to 20% & pay Sanofi to reimburse funded development expenses
- Under the 2015 agreement, the companies will share equal profits globally & co-commercialize Libtayo in the US. Sanofi will be responsible for commercialization outside the US. The regulatory reviews are ongoing for Libtayo + CT in advanced NSCLC in multiple markets, including the US & EU
Ref: Regeneron | Image: Regeneron
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
